. home.aspx


Bayer looks to leverage AI across the pharma value chain

March 21, 2018

Bayer has already shown more than a passing interest in artificial intelligence through its digital accelerator programme Grants4Apps, but the company’s use of the technology looks to be more wide-ranging and deep-seated than that. Talking to journalists after the company’s Financial News Conference late last month in Leverkusen, Germany, the president of Bayer Pharma Dieter Weinand spoke of his hopes for AI. The company is, he said, “all over this”, having already collaborated with the likes of Verily, the life sciences unit at Google parent company Alphabet, and IBM’s Watson and Deep Blue. “We’re looking into all these areas across the entire value chain, from R&D all the way to commercial.” Spearheading some of this work is Bayer’s LifeScience iHub, a Silicon Valley-based innovation centre set up in 2015 to focus on developing new digital solutions.